成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 99-07-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 99-07-0
Chemical Structure| 99-07-0
Structure of 99-07-0 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 99-07-0 ]

Related Doc. of [ 99-07-0 ]

Alternatived Products of [ 99-07-0 ]
Product Citations

Product Citations

Monta?o, Antonio R ; Masillati, Anas ; Szafran, Dani A , et al. DOI:

Abstract: The FDA's recent approval of pafolacianine, the first molecular targeted contrast agent for fluorescence-guided surgery (FGS), signifies a remarkable milestone in precision medicine. This advance offers new hope for cancer patients by enabling guided removal of cancerous tissues, where completed surgical removal remains a consistent challenge without real-time intraoperative guidance. For optimal surgical outcomes, delicate nerve tissues must be preserved to maintain patient quality of life. Despite advances in the clinical translation pipeline, the development of clinically viable nerve-specific contrast agents for FGS remains a significant challenge. Herein, a medicinal chemistry-based matrix design strategy was applied to effectively generate a synthetic roadmap permitting management of nerve-specificity within the near-infrared (NIR) oxazine fluorophore family. Many of these newly developed fluorophores demonstrated robust nerve-specificity and superior safety profiles, while also offering spectral profiles that are compatible with the clinical surgical FGS infrastructure. Notably, improving observed brightness in vivo enabled exceptional visibility of buried nerve tissue, a priority during surgical procedures. Critically, the lead probe showed a large dosage safety window capable of generating substantial contrast at doses 100x lower than the maximum tolerated dose. Following clinical translation, such NIR nerve-specific fluorophores stand poised to significantly improve outcomes for surgical patients by improving identification and visualization of surface and buried nerve tissues in real time within the surgical arena.

Keywords: Near-infrared (NIR) ; Fluorescence imaging ; Oxazine ; Nerve-specific imaging ; Fluorescence-guided surgery (FGS)

Purchased from AmBeed: ; ; ;

Product Details of [ 99-07-0 ]

CAS No. :99-07-0 MDL No. :MFCD00002264
Formula : C8H11NO Boiling Point : -
Linear Structure Formula :HOC6H4N(CH3)2 InChI Key :MESJRHHDBDCQTH-UHFFFAOYSA-N
M.W : 137.18 Pubchem ID :7421
Synonyms :

Calculated chemistry of [ 99-07-0 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.25
Num. rotatable bonds : 1
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 42.67
TPSA : 23.47 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.03 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.54
Log Po/w (XLOGP3) : 1.56
Log Po/w (WLOGP) : 1.46
Log Po/w (MLOGP) : 1.48
Log Po/w (SILICOS-IT) : 0.91
Consensus Log Po/w : 1.39

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.05
Solubility : 1.22 mg/ml ; 0.00889 mol/l
Class : Soluble
Log S (Ali) : -1.66
Solubility : 2.98 mg/ml ; 0.0217 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.9
Solubility : 1.72 mg/ml ; 0.0125 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 99-07-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 99-07-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 99-07-0 ]
  • Downstream synthetic route of [ 99-07-0 ]

[ 99-07-0 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 99-07-0 ]
  • [ 150188-64-0 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 9, p. 1310 - 1326
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 99-07-0 ]

Aryls

Chemical Structure| 619-60-3

[ 619-60-3 ]

4-(Dimethylamino)phenol

Similarity: 0.97

Chemical Structure| 91-68-9

[ 91-68-9 ]

3-Diethylaminophenol

Similarity: 0.95

Chemical Structure| 5882-48-4

[ 5882-48-4 ]

4-(Dimethylamino)phenol hydrochloride

Similarity: 0.95

Chemical Structure| 701-56-4

[ 701-56-4 ]

4-Methoxy-N,N-dimethylaniline

Similarity: 0.93

Chemical Structure| 15799-79-8

[ 15799-79-8 ]

3-Methoxy-N,N-dimethylaniline

Similarity: 0.93

Amines

Chemical Structure| 619-60-3

[ 619-60-3 ]

4-(Dimethylamino)phenol

Similarity: 0.97

Chemical Structure| 91-68-9

[ 91-68-9 ]

3-Diethylaminophenol

Similarity: 0.95

Chemical Structure| 5882-48-4

[ 5882-48-4 ]

4-(Dimethylamino)phenol hydrochloride

Similarity: 0.95

Chemical Structure| 701-56-4

[ 701-56-4 ]

4-Methoxy-N,N-dimethylaniline

Similarity: 0.93

Chemical Structure| 15799-79-8

[ 15799-79-8 ]

3-Methoxy-N,N-dimethylaniline

Similarity: 0.93

; ;